Corporate Profiles 2011

Corporate ProďŹ les 2011

A supplement to LifeSciences British Columbia Featuring: BC Preclinical Research Consortium Centre for Advanced Diagnostics The Centre for Drug Research and Development Farm Credit Canada Genome British Columbia GlaxoSmithKline Italian Trade Commission Kalgene Pharmaceuticals LifeLabs Pegasus Pharmaceuticals Pfizer Canada Premier Diagnostic PROOF Centre of Excellence Rx&D Seed IP Stemcell Technologies Syreon

The B.C. life sciences industry is ranked among the smartest and fastest growing research communities in the world.

Sponsored by

Published by

Corporate Profiles 2011.indd 1

2/15/11 7:50:26 PM

67$<,1* $+($' %< 67$<,1* $7 7+( )25()5217 2) ,1129$7,21

)URP UDGLFDO PHGLFDO EUHDNWKURXJKV WR LQFUHPHQWDO LPSURYHPHQWV WR H[LVWLQJ WUHDWPHQWV *OD[R6PLWK.OLQH EHOLHYHV WKDW HYHU\ VWHS IRUZDUG LV D VWHS LQ WKH ULJKW GLUHFWLRQ $V RQH RI &DQDGD·V OHDGLQJ UHVHDUFK EDVHG SKDUPDFHXWLFDO FRPSDQLHV ZH EHOLHYH LQ FRQWLQXRXV LQQRYDWLRQ EHFDXVH ZH NQRZ WKDW HYHU\RQH EHQHÃ&#x20AC;WV IURP PHGLFDO DGYDQFHPHQWV ELJ RU VPDOO $W *6. ZH VWD\ DKHDG E\ VWD\LQJ FRPPLWWHG WR SURJUHVV 'LVFRYHU PRUH DW *6. FD

Corporate Profiles 2011.indd 2

2/15/11 7:31:09 PM

$ " %

" &

" '

" (

!

"

"

#

Corporate Profiles 2011.indd 3

2/15/11 7:31:09 PM

Supporting the internationalisation of Italian firms and the consolidation of their business relationships in foreign markets, the Italian Trade Commission is proudly showcasing the Italian biotech scenario with growing opportunities at BioPartnering 2011.

Italy at

The successful Italian testimonials participating at BioPartnering 2011 are: A. Menarini IFR www.menarini.it C. Musso: cmusso@menarini.it Areta International www.aretaint.com L. Cavenaghi: lcavenaghi@aretaint.com Assobiotec Industry Association: www.assobiotec.it L. Vingiani: assobiotec@federchimica.it Bracco Imagining spa www.braccoimaging.com D. Fujii: dennis.fujii@bru.bracco.com CROM Group www.cromgroup.com M. Mosconi: margherita.mosconi@cromgroup.com Menarini Biotech srl www.menarini-biotech.com C. Panzarella: cpanzarella@menarini-biotech.it Pharma & Biotech Advisors P. Barbanti: barbanti@pharmaebiotech.com Proge Farm srl www.progefarm.it E. Tosi: etosi@progefarm.it Proge Medica srl G. Dondi: progemedica@libero.it Recordati Industria Chimica e Farmaceutica spa www.recordati.it.

P. Ferlenga: ferlenga.p@recordati.it Italian Trade Commission Trade Promotion Section of the Consulate Generale of Italy 180, Dundas Street West Suite 2002, P.O. BOX N째2 M5G 1Z8 Toronto, Ontario, Canada toronto@ice.it Tel: +1 416 598 1566 Fax: +1 416 598 1610

Corporate Profiles 2011.indd 4

www.italtrade.com 2/15/11 7:31:11 PM

Supplied by

><EFD< 9I@K@J? :FCLD9@8

nnn%^\efd\YZ%ZX

>\efd`Zj i\j\XiZ_ jgXej Xcc Xi\Xj f] c`]\ jZ`\eZ\j

K

he 21st century faces issues around protecting our food supply, finding sustainable sources of energy, keeping our population healthy, and the need to adapt to the effects of climate change.

Genomics’ greatest potential is that it possesses tools for addressing these key global challenges. Genome British Columbia aims to provide positive impacts and solutions by investing in, managing and enabling large-scale genomics and proteomics research projects and technology platforms. Over the past decade the research projects it has funded have made impacts in areas of strategic and economic importance to British Columbia, Canada and the world, including human health, forestry, fisheries, agriculture, bioenergy, mining and the environment. In addition, a critical element of responsible genomics research is to provide a forum through which accompanying environmental, ethical, economic, legal and social issues can be explored so that the context for scientific research remains focussed and relevant to society. Genome BC’s research portfolio is funded by the Province of British Columbia, the government of Canada through Genome Canada and Western Economic Diversification and over 100 international and industry partners.

for determining the sequence of a cancer patient’s genome that are faster, more efficient and targeted. These technology advances are enabling the practical application of personalized medicine.

Together, with their clinical colleagues, they have made cancer breakthroughs such as the identification of a gene mutation in a prevalent type of ovarian cancer, the first-ever sequencing of a breast cancer genome, and the identification of a mutation in a specific gene linked to B-cell lymphoma.

:c\Xe`e^ lg d`e`e^ j`k\j n`k_ d`Zif$fi^Xe`jdj Genomics researchers are exploring ways to put micro-organisms to work as sustainable bioremediation agents in the cleanup of wastewater in mine sites. “There are micro-organisms out there that can do all sorts of things, including the detoxification of water,” says UBC scientist Sue Baldwin, who is leading the $1.5-million research project. “We are relying on microbes that are already present in the environment to do this, and using genomics to determine how to create the conditions in which they will thrive.” The researchers will determine the conditions necessary to ensure that micro-organisms that digest metal toxins will continue to do their jobs over time.

A snapshot of diversity in genomics research

Klie`e^ [\X[ nff[ `ekf e\n ]l\c =`^_k`e^ ]le^` \g`[\d`Zj `e gcXekj Xe[ ki\\j Fungi or “rusts” attack and damage plants and trees, affecting food production, threatening ecosystems and leading to billions of dollars in lost revenues from the agricultural and forestry sectors.

Richard Hamelin from UBC and Guus Bakkeren from Agriculture and Agri-Food Canada are working on identifying the key genes involved in rust infection in order to be able to more quickly detect and monitor rusts and more effectively prevent infection.

“A key aspect of these diseases is genetic variation that allows rusts to overcome host resistance,” say Dr. Hamelin. The scientists hope to find a core set of genes that relate to resistance, and eventually identify an early-warning system for disease outbreaks.

<eXYc`e^ Y\kk\i ZXeZ\i i\j\XiZ_ While the human genome project took about 15 years and $3 billion, today’s next-generation sequencing technologies will soon make the “$1,000-genome” a possibility. The research of scientists at the Michael Smith Genome Sciences Centre including Marco Marra, Robert Holt and Steven Jones is resulting in technologies

Corporate Profiles 2011.indd 5

Devastation caused by the mountain pine beetle infestation in BC has created large amounts of unmarketable lodgepole pine that could supply the biofuel industry for the next 20 years and beyond. Jack Saddler from UBC is leading a research project using genomics to enhance enzymes that act as nature’s catalysts, liberating fermentable sugars from wood so it can be used for biofuels.

“Trees are a huge store of chemical energy that can be converted into liquid biofuel,” he says. Dr. Saddler is confident that the solution they find for coniferous trees will be transferable to deciduous varieties, creating a renewable source of biofuel stock for future generations.

Over the past 10 years, Genome BC has invested in $450 million in BC-based genomics research and plans to invest another $340 million over the next give years.

Contact: Richard Howlett Email: rhowlett@genomebc.ca Phone: 604-637-4379

2/15/11 7:31:11 PM

Supplied by

GIFF= :<EKI< F= <O:<CC<E:<

nnn%giff]Z\eki\%ZX

9`fdXib\i jfclk`fej ]fi _\Xck_ ZXi\

K

he Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) is a unique, federally-funded, notfor-profit organization that discovers, develops and implements novel blood-based biomarker tests to prevent and better manage hea r t, lung, a nd k idney failure in individual patients.

The PROOF Centre leverages advanced technologies, diverse expertise, and global partners multisectorally in pursuing its vision. Th is synthesis allows the PROOF Centre to create novel and powerful tests, reduce development costs and business risks. The biomarker solutions also accelerate relief for our burdened healthcare systems and the patients at risk or suffering from organ failure.

and immune rejection, allowing the best treatments to be chosen and applied before the damage is done. Building on a successful pipeline, we are discovering and developing new biomarker solutions for chronic kidney disease, chronic obstructive pulmonary disease, and acute and chronic heart failure.

N\ dfm\ [`jZfm\ip `ekf k_\ Zc`e`Z ]Xjk\i%

Heart, lung and kidney diseases together represent a growing burden in Canada and around the world. For millions of patients suffering under this burden, impaired organ function and organ failure have a devastating impact. The socio-economic impact of organ failure is enormousâ&#x20AC;&#x201D;one in four Canadians is estimated to be at risk. Thus, the mission to discover, develop, commercialize, and implement bloodbased biomarker tests in clinical settings to better manage patients with heart, lung, and kidney failure is strongly compelling.

Bridging the gap from discovery of new diagnostics to their routine use in the clinic is complex. Our team, infrastructure, assets, experience, and strategies overcome barriers and accelerate this process such that we can bring health benefits to patients sooner, create value, reduce costs and business risk for our partners, and relieve our burdened health system promptly. We begin with a clinical need, one for which biomarkers bring potential value. This approach helps us bypass common pitfalls such as clinical failure due to over-reliance on preclinical models that prove irrelevant in humans, and focus our time and resources effectively. Our hub of expert people and teams enables us to deal with development hurdles as parallel processes that inform each other in real time rather than as a lengthy series of siloed activities. We leverage valuable assets, such as high-technology platforms, and quality patient cohorts, for maximal efficiency.

N\ Xi\ X efk$]fi$gifĂ&#x201D; k _lY%

N\ f]]\i mXcl\ kf gXike\ij%

We are experienced, proven leaders and cross-disciplinary teams from health care, business, and academia. We put our rich strategic networks and diverse range of expertise and resources to work for the PROOF Centre, anchored at St. Paulâ&#x20AC;&#x2122;s Hospital and hosted by the University of British Columbia in Vancouver, Canada. We were established as an NCE Centre of Excellence for Commercialization and Research in 2008 based on over five years of previous success in biomarker discovery and development.

We build on extended networks throughout industry, health care and academia, and continually seek collaborations and strategic partnerships to enhance biomarker discovery and clinical validation as part of our mandate to reduce the burden of organ failure. Our flexible business model and end-to-end expertise allows opportunity to decrease risk for all partners involved. Our model also creates training and research opportunities in science and business. Importantly, we will reduce the financial burden on the healthcare system by preventing disease and improving health.

N\ Xi\ ]XZ`e^ X _l^\ \g`[\d`Z%

N\ [\m\cfg Ycff[ k\jkj kf gi\[`Zk fi [`X^efj\ fi^Xe ]X`cli\% Replacing suboptimal diagnostics with simple, effective blood tests is our goal; we will improve quality of life and health outcomes for patients, help physicians provide patient-centered care, and decrease direct and indirect costs to our healthcare system and our society. Forging commercialization paths for development of top Canadian innovations will also give a much-needed boost to our economic health. We focus on developing blood tests for non-invasive diagnosis and prediction of organ failure

Corporate Profiles 2011.indd 6

Can companion diagnostics speed your drug development pathway? Seeking patient cohorts for your external validation studies?

Looking to obtain expert contract services related to biomarkers or organ failure? Contact us to learn more about partnering or collaborating with the PROOF Centre.

Contact: Leah Lockhart Email: leah.lockhart@hli.ubc.ca Tel: 604-806-9853

2/15/11 7:31:12 PM

Supplied by

:<EKI< =FI ;IL> I<J<8I:?

8E; ;<M<CFGD<EK :;I;

nnn%Z[i[%ZX

9i`[^`e^ k_\ Zfdd\iZ`Xc`qXk`fe ^Xg Successful drug development through collaboration

:

DRD draws on the research excellence and diversity of scientists working at academic and health research institutions, who represent an investment of over $1.4 billion per year in research. CDRD supports numerous projects each year. Scientific and technical expertise guided by business discipline, allows CDRD to make practical decisions regarding promising technologies. Those that hold promise as products are advanced to the next stages for development.

8ZZ\jj Xe \ok\ej`m\ `eefmXk`fe e\knfib There is growing interest from the pharmaceutical industry to externalize innovation and companies are looking at new models for accessing early stage research. CDRD provides unprecedented, reduced-risk access to new pipeline opportunities for pharmaceutical and biotech companies. CDRD, through its partnerships with many affiliated institutions, is connected to an extensive network of world class scientists working in many disease areas, as well as to key opinion leaders, and research driven clinical researchers across Canada and with institutions in the US, Europe, Australia, and Asia. CDRD broadened its reach of affiliated institutions to go beyond British Columbia to include McMaster University, Thompson Rivers University, and Dalhousie University as well as MaRS Innovation – representing 14 leading Toronto-research based institutions.

<ok\e[ ZXgXZ`kp n`k_ \og\ik`j\ Xe[ `e]iXjkilZkli\ CDRD can provide specialized expertise in areas that an organization does not have in-house, or for companies who choose to externalize development. CDRD’s divisions cover the spectrum of pre-clinical drug development and are professionally managed and operated by personnel with experience and track records in drug development research and business. Working with principal investigators, CDRD helps overcome scientific and project management roadblocks by identifying critical issues required to establish therapeutic potential; conducting pivotal pilot experiments; identifying collaborations and facilitating collaborative grant requests; and project management for multi-investigator programs.

CDRD’s drug development platform has operational facilities located on the campuses of University of British Columbia, Simon Fraser University, and the British Columbia Cancer Agency. In addition to the newly created biologics department, CDRD has five divisions that support the drug development process including target validation; screening; medicinal chemistry; drug formulation and delivery; and pharmacology and toxicology.

Corporate Profiles 2011.indd 7

:;I; @eefmXk`fe =le[j CDR D ha s entered i nto st rateg ic pa r t nersh ips to create ded ic ated Innovation Funds designed to support the applied research necessary to develop a technology towards commercialization. As another source of non-dilutive capital, CDRD projects are eligible to apply to these Innovation Funds to support costs, such as consumable and patent expenses. The current Innovation Funds include the Pfizer-CDRD Innovation Fund; the Genome BC-CDRD Development Fund; and the Western Canada Innovation Fund, which was created with the support of Johnson & Johnson and the Provinces of British Columbia and Alberta.

@dgifm\ k_\ Z_XeZ\j k_Xk e\n [il^j ^f kf dXib\k CDRD operates as a not-for-profit entity, allowing it to work seamlessly with public research institutions. Its commercial arm, CDRD Ventures Inc., advances a carefully selected portfolio of drug candidates through preclinical development, ultimately licensing to pharmaceutical and biotech partners or creating spin-off companies. The company also offers local life science companies access to CDRD’s expertise and infrastructure through collaborations to advance programs to key valuation points or to improve their ability to attract investment.

@e[ljkip gXike\ij_`gj In addition to the strong collaborations established with its funding partners, CDRD is pursuing strategic partnerships with pharmaceutical companies and other centres of excellence across Canada as well as in the United States, Europe, and Asia. CDRD, through its commercial arm, also provides assistance to local biotech companies by leveraging its technical strengths and research capabilities to support early stage R&D programs.

I\[lZ\ i`jb# `eZi\Xj\ kiXejgXi\eZp Strategic partners, venture capital firms, and funding agencies can look to CDRD to reduce development risk and provide a more transparent means to invest in drug development projects. From the outset, CDRD instills scientific and business discipline in the development process, with a focus on commercialization that optimizes resources. The diversity and breadth of development projects combined with infrastructure and expertise improves the chances for the successful commercialization of new therapeutics.

To learn more, please contact: Karimah Es Sabar, Senior VP, Business & Strategic Affairs at kessabar@cdrd.ca or 604.221.7750

2/15/11 7:31:12 PM

Supplied by

G=@Q<I :8E8;8 @E:

nnn%gÔq\i%ZX

;\[`ZXk\[ kf _\cg`e^ ZXeX[`Xej c`m\ _\Xck_`\i c`m\j

D

uch of Pfizer Canada’s work happens w it h i n t he loca l communities it serves and we are proud to be active in British Columbia, with a focus reflecting a core belief that to be truly healthy, it takes more than medication. Pfizer is also a proud partner of Life Sciences British Columbia as it shares their vision for a vibrant and successful biotechnology sector in the province.

Pfizer is very proud of the work accomplished in British Columbia over the past few years.

@em\jk`e^ `e Zfddle`k`\j Xe[ jgfikj Zlckli\ In 2010, Pfizer Canada invested approximately $1 million in communities across the province. The United Way, as well as various other not-for-profit associations, receive grants from Pfizer Canada to help support the valuable work they do.

In partnership with two other Rx&D member companies, Pfizer has made a significant partnership investment with the Government of British Columbia and the BC Ambulance Service towards the Advanced Coronary Treatment (ACT) Foundation to bring the ACT High School CPR program to all BC Public Secondary Schools. This investment will help provide the necessary test mannequins for high school students to learn the essentials of CPR training.

Pfizer is also a proud sponsor of the Canadian Paralympic Team and like many Canadians, cheered the team at the March 2010 winter games. Pfizer has been a supporter of Canada’s paralympians since 1996.

If you are a member of a not-for-profit group or association and would like to learn more about our community investment program, please visit: http://pfizer.ca/community

9l`c[`e^ jkife^ gXike\ij_`gj Pfizer is committed to building strong partnerships in a variety of settings that help to keep British Columbians healthy. Pfizer, the BC Cancer Agency and the Prostate Center at Vancouver General Hospital have come together to tackle new targets for the treatment of breast, ovarian and prostate cancer. Pfizer has dedicated $9 million to this research collaboration which is Pfizer’s single largest investment in BC’s public medical research infrastructure.

The Pfizer/Heart and Stroke Foundation of BC & Yukon Chair in Cardiovascular Disease Prevention Research at St. Paul’s Hospital is going into its third year. Pfizer contributed $1.25 million towards this initiative, which is the first Canadian research chair in cardiovascular disease prevention and health policy.

Pfizer continues to invest in the Pain BC Society to support its work to improve the quality of timeliness of care for British

Corporate Profiles 2011.indd 8

Columbians suffering from chronic pain. Through an investment of $160,000, the society was able to establish a Framework for Action to initiate its work to increase the number of general practitioners treating pain and decreasing wait times for access to treatment.

P f i z er, i n p a r t ner s h ip w it h the Centre of Excellence for the Prevention of Organ Failure (PROOF), is also committed to improving the standard of care and quality of life for Canadians faced with heart, lung and kidney failure.

Pfizer believes in supporting the acceleration of knowledgetranslation and commercialization of new ideas. Pfizer has a multi-million dollar partnership with BC’s Centre for Drug Research and Development (CDRD) with the creation of the Pfizer-CDRD Innovation Fund.

Recognizing the changing environment, Pfizer has invested in a dedicated field force responsible for aligning to the needs of those leading primary care improvement. These account managers, health networks do not carry samples or discuss specific products, but rather act as connectors to support the improvement in chronic disease management including programs like Healthcare Team Effectiveness (H.T.E.), an innovative process designed to develop excellence in teamwork

@em\jk`e^ `e \[lZXk`fe Pfizer is a proud supporter of the Ripples of Hope Award which was initiated by Dr. Michael Hayden. Ripples of Hope represents an endowment fund that will form a pillar for trainees in the areas of global health, rare diseases, mental health and biotechnology. Pfizer is proud to have pledged $700,000 toward this fund, specifically in support of the mental health and rare diseases traineeships.

In 2011, Pfizer will sponsor various student education activities such as the Pfizer Prize for Excellence in Pharmaceutical Sciences at UBC and the Student Biotechnology Network. Our company is also pleased to be supporting the success of the Year of Science community education initiatives, lead by the Ministry of Science and Universities.

Cffb`e^ kf k_\ ]lkli\ Ensuring good health is a priority for British Columbians, and Pfizer Canada looks forward to continuing to work with government, academics and other stakeholders to help the province achieve this important goal.

Contact: Pfizer Canada – Corporate Communications Email: corporate.affairs.canada@pfizer.com Tel: 514-695-0500 or 1-877-633-2001

2/15/11 7:31:13 PM

Supplied by

C@=<C89J

nnn%c`]\cXYj%Zfd

C`]\CXYj1 Pfli gXike\i `e `eefmXk`fe

C

ifeLabs Medical Labor ator y S er v ic e s , t he largest diagnostic laboratory in Canada, has been partnering in the creation of health innovations for over 50 years. As an important member of an extended healthcare team, we play a vital role in the delivery of patient-focused care. Each

year, we provide more than 50 million laboratory tests to over 10 million patients and nearly 20,000 physicians in Canada.

More than a decade ago, LifeLabs recognized that the future of laboratory diagnostics would be shaped by emerging genetic technologies and developed molecular diagnostics as a core capacity to improve the quality of lab diagnoses. Now, years later, the Molecular team is able to provide faster, more sensitive results using advanced costeffective techniques.

8 ]fZlj fe hlXc`kp

Studies estimate that up to 80% of all clinical treatment decisions are based on results from laboratory tests. Our test results enable healthcare providers to better prevent, diagnose, treat and monitor illness and disease in patients, while biotechnology and pharmaceutical companies rely on our lab results and specimen collection networks for effective clinical trials. LifeLabs is a key partner in delivering better outcomes in patient care.

LifeLabs’ BC-based labs were the first medical laboratories in the province to achieve ISO 15189 accreditation – an international quality standard.

Medical quality is promoted by our team of medical scientific experts. This widely respected medical team of Microbiologists, Hematopathologists, and Biochemists guide the testing services provided by LifeLabs as well as support physicians by providing consultation services to assist in the interpretation of test results.

Jlggfik`e^ XZZ\jj kf ZXi\

GXike\i`e^ ]fi Y\kk\i i\jlckj

LifeLabs’ extensive infrastructure means patients and physicians can access our services quickly, conveniently and close to home – removing barriers to patient participation in studies and trials by providing the necessary infrastructure for specimen collections.

With an integrated network of courier services, specimen collection centres, testing facilities and medical professionals, we are able to provide local access to regional and national expertise in laboratory testing.

Most test results are available to physicians and caregivers within hours of specimen collection, and by providing results electronically, they can access this information as soon as it is available.

As a national organization, LifeLabs has the capacity to collaborate broadly across the country. Our position as a major laboratory services provider makes us an ideal partner to government, academia and industry.

We work with research institutions and other healthcare providers to identify the best possible diagnostics tools to raise standards in patient care.

We also work closely with patient advocacy organizations, chronic disease groups and pharmaceutical organizations to support advancements in disease management and treatment and an improved quality of life for patients living with chronic illnesses.

Through our team of dedicated employees and focus on access, innovation, quality and results we are well positioned to make a significant difference in the health and well-being of Canadians.

Contact LifeLabs today to explore innovative partnership opportunities with a leading lab services provider.

8e `eefmXk`m\ XggifXZ_ We invest in new technologies and have developed novel methodologies and approaches that have been presented at international scientific conferences and published in peer-reviewed medical journals.

In the 1990s, we envisioned a patient-centred future where lab results would be available electronically to caregivers, pulling data from multiple lab sources to provide a single cohesive report.

LifeLabs was a partner in the creation of Excelleris, a software and services health information management company dedicated to providing healthcare professionals with fast, accessible patient information.

Corporate Profiles 2011.indd 9

Contact: Les Jickling, Director, Business Development Email: les.jickling@lifelabs.com Tel: 604-412-4429

2/15/11 7:31:14 PM

Supplied by

JK<D:<CC K<:?EFCF>@<J @E:

nnn%jk\dZ\cc%Zfd

JK<D:<CC K\Z_efcf^`\j @eZ Æ 9:Ëj cXi^\jk Y`fk\Z_ ZfdgXep

S

TEMCELL Technologies Inc is a privatelyowned biotechnology company that helps power leading-edge life science research around the world. Scientists performing stem cell, immunology, cancer, regenerative medicine and cellular therapy research are among those who rely on our cell culture media, cell separation products and ancillary reagents.

We have over 400 science-oriented employees, including 100 PhDs / MScs working in the creation of novel products, providing consistent, unfailing quality in producing these products, and by standing with our customers around the globe to provide training, one-on-one assistance and technical support.

Driven by our love of science, and our passion for quality, STEMCELL now delivers over 1500 products to more than 70 countries worldwide.

Jg\Z`Xc`q\[ d\[`X gif[lZkj STEMCELL’s first product, MethoCult®, quickly became the world’s best selling methylcellulose-based medium for growing and characterizing blood-forming stem cells by in vitro colony assays and is now considered the industry standard.

Our scientists continue to develop media to support academic and industrial researchers in the standardization of stem cell research. This includes the development of standardized media for the expansion and evaluation of stem and progenitor cells from many sources including: hematopoietic, embryonic, induced pluripotent, mesenchymal, neural and a variety of epithelial tissues including mammary and prostate.

:\cc j\gXiXk`fe gif[lZkj STEMCELL’s cell separation products allow researchers to isolate virtually any cell type, including immune, hematopoietic, mammary and tumour cells. In addition to off-the-shelf cell separation kits, STEMCELL offers customized cell separation products. Working together with our knowledgeable technical support team, researchers can access STEMCELL’s expertise to design specific kits to meet their unique needs.

The platforms used to isolate cells include EasySep® – an immunomagnetic approach where cells are bound to antibodylinked magnetic particles and separated using a magnet, and RosetteSep® – an immunodensity approach, where unwanted cells are removed using antibodies linked to red blood cells and separated using density-gradient centrifugation.

I\j\XiZ_ `ejkild\ekj In addition to development of media and cell separation kits, STEMCELL has also developed a number of instruments to automate life science research. RoboSep® is a fully automated system for cell separation using our EasySep® immunomagnetic approach

Corporate Profiles 2011.indd 10

to save technicians time and to standardize cell separation procedures. RoboSep® eliminates the hands-on steps involved in cell separation, including reagent addition, incubation, and pipetting.

We have recently developed a revolutionary new instrument, STEMvision, to automate the identification and counting of hematopoietic colony-forming cell assays required in bone marrow research, cord blood banks and transplantation labs. This standardizes these tests, removing the variability associated with human counting and increasing lab capacity.

Our new ClonaCell ™ EasyPick, developed in collaboration with Hamilton Robotics, automates clone isolation in a high throughput manner. Optimized for use with ClonaCell ™ semi-solid media, our platform offers rapid and efficient development of cell lines for biopharmaceutical production.

8 ^cfYXc \ogfik\i n`k_ @JF Z\ik`ÔZXk`fe STEMCELL Technologies has solid manufacturing capabilities in our headquarters in the Lower Mainland. We are proud to have earned ISO 13485:2003 Certification for our research, manufacturing and shipping facilities in Canada, the US and France.

Our processes incorporate rigorous selection of raw materials and quality control processes. STEMCELL knows that a number of other factors also contribute to achieving consistent research results for our customers, including training and access to timely and effective technical assistance.

?\cg`e^ jZ`\ek`jkj cfZXccp Xe[ ^cfYXccp STEMCELL is committed to working together with scientists to develop new products that will help perform their experiments better and faster. If there is a product or service that is not offered, STEMCELL’s team is able to discuss specific experimental requirements with researchers, and design and manufacture customized reagents for their needs.

STEMCELL’s Contract Assay Service works with pharma and biotech scientists to develop and perform flexible custom-designed experiments. By harnessing STEMCELL’s industry-standard reagents and extensive stem cell biology expertise, pharmaceutical and biotech companies can rapidly screen products at the earliest stage of development, thereby saving valuable time and resources in the development process.

:fdd`kk\[ kf jZ`\eZ\ Xe[ jZ`\ek`jkj STEMCELL’s teams have participated in more than 200 collaborative projects in 18 different countries. With over $3.5 million dollars in contributions to the Canadian Stem Cell Network, STEMCELL is actively driving Canadian research. Locally, STEMCELL has collaborated with and helped fund over forty research groups. For more information about STEMCELL Technologies, please visit www.stemcell.com.

2/15/11 7:31:14 PM

Supplied by

G<>8JLJ G?8ID8:<LK@:8CJ >IFLG @E:%

nnn%gg^`eZf%Zfd

C`]\cfe^ n\cce\jj n`k_ G\^Xjlj

G

egasus Pharmaceuticals Group Inc. (“Pegasus”) is a Canadian high-tech biopharmaceutical company that is specialized in research & development, manufacturing and commercialization of phytocompounds and biologically active peptides.

Pegasus ta kes a leading position in natura l herba l drug modernization and has received enormous funding from various authorities, especially, the National Research Council of Canada.

With talented scientists of diverse expertise and whole-hearted dedication, Pegasus has developed several world-leading technologies in natural herbal drug R & D. 1) Selective Metabolites Compound Drug (SMCD) technology helps scientists quickly characterize active chemical ingredients in long-used traditional herbal drugs such as Ginseng. Also, it revolutionizes the manufacture of many herbal drugs to meet the FDA requirements for new drug application. Profiting from SMCD, Pegasus has gained a thorough understanding of active chemicals in Ginseng, one of which shows a strong stimulatory effect on bone marrow and stem cell growth, typically useful for bone marrow reconstitution after bone marrow transplantation and recovery after cancer chemotherapy. In addition, Pegasus has identified several other promising drugable anti-cancer candidates which show great cytotoxic effect on cancer cells and inhibitory effect on multidrug resistance protein P-GP. 2) Oral Bioavailability Enhancement Technology (OBET) comprises a series of innovative formulation techniques which drastically improve the oral bioavailability of herbal drugs more than fivefold to a level sufficient to achieve pharmacological activity upon oral administration. OBET technology tackles the difficulties in developing traditional herbs into modern oral preparations with regard to oral effectiveness. Based on above technologies, Pegasus has acquired five ratified patents and seven pending ones in Canada, USA, European Union, China, Singapore, etc.

Pegasus has established a peptide research laboratory, one of few laboratories in the world able to provide commercial peptide array services. This cutting-edge technology allows scientists to investigate protein-protein interactions in a robust and highthroughput way. Using peptide array, Pegasus has mapped first in the world, the whole antigenic epitopes of SARS coronavirus in 2004, and the latter could be used for vaccine and protective antibody development. Furthermore, Pegasus has developed a unique peptide design algorithm enabling researchers to cost- and

Corporate Profiles 2011.indd 11

time-efficiently design and find active peptides for target proteins. Combined with peptide array, this algorithm has assisted our scientists in finding promising peptide candidates for treatment of Parkinson’s disease, HIV/AIDS, thromboembolic diseases and anaphylaxis.

Taking advantage of the SMCD and OBET technologies, Pegasus has successfully developed four Careseng® product lines of anti-cancer, stem-cell stimulation, health promotion and cosmetics, which feature high oral bioavailability and well-recognized effectiveness. Supported by well-designed pre-clinical studies and convincing clinical trials, four Careseng® products have been approved as new anti-cancer and cardiovascular drugs in the Republic of Georgia since 2007. New drug applications in Russia, Ukraine, Uzbekistan and Moldova are also under way. To date, Pegasus has completed preclinical studies of a drug candidate for bone marrow recovery and reconstitution, and the application for FDA IND will be submitted in late 2011.

Pegasus has forged extensive collaborations with worldwide universities, research institutes, hospitals and clinics, including University of California, Los Angeles, University of British Columbia, Simon Fraser University, University of Alberta, Tokyo University of Science, Chinese Academy of Medical Science, Taipei College of Physical Education and Sino-Japan Friendship Hospital (Beijing, China). Also, Pegasus has established several subsidiaries and joint ventures in Mainland China, Taiwan, Singapore and several other countries in Southeast Asia, aiming to double its market share in the next three years. Currently, Pegasus and the National Cancer Center of Georgia are cooperatively establishing a world-class cancer treatment and research center, helping translate up-to-date advances in cancer research into patients’ wellness.

In the past fifteen years of research and development of natural herbal drugs and active peptides, Pegasus has grown into a multinational corporation with over 200 employees. With its revolutionary technologies and gifted scientists, Pegasus will continue to play a leading role in herbal drug modernization and is committed to delivering its knowledge of health benefits from traditional herbal drugs to and making a better life for patients.

Contact: James Cao, Vice President; Clint Cheng, Business Development Director; Martin Wang, R&D Director Email: info@pegasuspharm.com; Tel: 604-303-9952

2/15/11 7:31:15 PM

Supplied by

9I@K@J? :FCLD9@8 GI<:C@E@:8C I<J<8I:? :FEJFIK@LD nnn%YZgiZ%ZX

IX`j`e^ k_\ YXi1 9l`c[`e^ gi\Zc`e`ZXc i\j\XiZ_ jpe\i^`\j `e 9i`k`j_ :fcldY`X Y\pfe[

<

TUBCMJTIFE JO UIF #SJUJTI $PMVNCJB 1SFDMJOJDBM 3FTFBSDI $POTPSUJVN #$ 13$ JT BO PSHBOJ[FE QMBUGPSN UISPVHI XIJDI CJPNFEJDBM SFTFBSDIFST JO BDBEFNJB BOE JOEVTUSZ DBO BDDFTT JO WJWP SFTFBSDI NPEFMT BOE IJHI RVBMJUZ QSFDM J O JD B M TFS W JDFT SFTFB SDI GBDJMJUJFT TQFDJBMJ[FE FRVJQNFOU BOE )21 PO B GFF GPS TFSWJDF CBTJT $VSSFOU NFNCFST JODMVEF TFWFSBM QSPWJODJBM .FNCFS *OTUJUVUJPOT BOE 'BDJMJUJFT JODMVEJOH UIF 6#$ $FOUSF GPS %JTFBTF .PEFMJOH 6#$ 3FEFSJWBUJPO 'BDJMJUZ $FOUSF GPS .PMFDVMBS .FEJDJOF BOE ćFSBQFVUJDT $..5 #$ $BODFS "HFODZ #$$" 6#$ .3* 3FTFBSDI $FOUSF BOE UIF 6OJWFSTJUZ PG /PSUIFSO #SJUJTI $PMVNCJB 6/#$ ćJT OFUXPSL XJMM TPPO FYQBOE UP JODMVEF 4JNPO 'SBTFS 6OJWFSTJUZ 6OJWFSTJUZ PG 7JDUPSJB +BNFT )PHH 3FTFBSDI $FOUSF BU UIF 1SPWJEFODF )FBSU -VOH *OTUJUVUF BOE 53*6.'

Gi\Zc`e`ZXc j\im`Z\j1 4FSWJDFT QSPWJEFE CZ #$ 13$ GBMM JOUP UXP NBJO TFSWJDF DPSFT 5IF 1IBSNBDPMPHZ BOE *NBHJOH $PSF QSPWJEFT QSFDMJOJDBM QIB S NBDPMPH Z UPY JDPMPH Z TFS W JDFT QIB S NBDPL J OFU JD T QIBSNBDPEZOBNJDT FGGJDBDZ UPYJDJUZ TNBMM BOJNBM (-1 OPO JOWBTJWF JNBHJOH BOE .3* 5IF 5SBOT"3$ $PSF QSPWJEFT USBOTHFOJD QIFOPUZQJOH SFEFSJWBUJPO FNCSZP USBOTGFS BOE DSZPQSFTFSWBUJPO BOE PUIFS TQFDJBMJ[FE TFSWJDFT JO SFQSPEVDUJWF UFDIOPMPHJFT " OFX 1IFOPHFOPNJDT $PSF XJMM CF PQFOJOH TPPO *O BEEJUJPO #$13$ QSPWJEFT TFSWJDFT TVDI BT QSPKFDU QMBOOJOH WBMJEBUJPO PG TUVEZ QSPUPDPMT BOE QSPDFTTFT DPOUSBDUVBM BHSFFNFOUT RVBMJUZ BTTVSBODF SFQPSUJOH BOE DFOUSBMJ[FE CJMMJOH PO CFIBMG PG NFNCFS GBDJMJUJFT BOE FYUFSOBM BDBEFNJD DPSQPSBUF BOE JOEVTUSZ DMJFOUT

9: GI: ^fXcj1 t 1SPWJEF UIF FOUJSF CJPNFEJDBM DPNNVOJUZ XJUI JOUFHSBUFE BOE DPTU FGGFDUJWF BDDFTT UP TUBUF PG UIF BSU UFDIOPMPHJFT GPS UIF HFO FSBUJPO NBJOUFOBODF BOE DIBS BDUFSJ[BUJPO PG JO WJWP NPEFMT PG IVNBO EJTFBTF t 'PTUFS DPNNVOJDBUJPO BOE DPM MBCPSBUJPO CFUXFFO JOTUJUVUJPOT BOE QIBSNBDFVUJDBM MJGF TDJFODFT DPN QBOJFT FOBCMF TIBSJOH PG SFTPVSDFT JODSFBTF FEVDBUJPO PQQPSUVOJUJFT JODSFBTF FďDJFODZ JO QSFDMJOJ DBM SFTFBSDI BOE EJWFSTJGZ SFTFBSDI QPSUGPMJPT UP JODMVEF GFF GPS TFSWJDF BDUJWJUJFT t %FWFMPQ BO JOUFSOBUJPOBMMZ DPNQFUJUJWF DPMMBCPSBUJWF SFTFBSDI OFUXPSL GPS QSFDMJOJDBM SFTFBSDIFST BDSPTT #SJUJTI $PMVNCJB BOE CFZPOE t %FWFMPQ DVUUJOH FEHF UFDIOPMPHJFT GPS UIF QSPEVDUJPO PG JO WJWP NPEFMT PG IVNBO EJTFBTF UIBU XJMM SFWPMVUJPOJ[F IFBMUI DBSF t &OBCMF USBOTMBUJPOBM SFTFBSDI DSJUJDBM GPS DPNNFSDJBM PQQPSUVOJ UJFT JO UIF CJPUFDIOPMPHZ JOEVTUSZ

JkiXk\^`Z gXike\ij_`gj1 *O BEEJUJPO UP TUSPOH DPMMBCPSBUJPOT FTUBCMJTIFE XJUI NFNCFS JOTUJUVUJPOT #$ 13$ JT JOUFSFTUFE JO QVSTVJOH OFX TUSBUFHJD QBSU OFSTIJQT XJUI QIBSNBDFVUJDBM DPNQBOJFT DFOUSFT GPS FYDFMMFODF BOE PUIFS QSFDMJOJDBM SFTFBSDI DPOTPSUJVNT BDSPTT $BOBEB BT XFMM BT JO UIF 6OJUFE 4UBUFT &VSPQF BOE "TJB *ODSFBTF JO NFNCFS TIJQ BOE QBSUJDJQBUJPO JO UIF #$ 13$ GPTUFST OFX DPMMBCPSBUJPOT CFUXFFO SFTFBSDI HSPVQT BOE JOEJWJEVBMT XIP DPOEVDU TJNJMBS PS DPNQMFNFOUBSZ BOJNBM SFTFBSDI QSPDFEVSFT 5IJT MFBET UP JODSFBTFE FďDJFODZ BOE PVUDPNFT PG SFTFBSDI QSPKFDUT UISPVHI LOPXMFEHF FYDIBOHF

9: GI: d`jj`fe `j kf dXkZ_ e\\[j n`k_ ZXgXZ`kp1

9\e\Ôkj f] gXik`Z`gXk`fe1

ćF NJTTJPO PG #$13$ JT UP QSPWJEF BDDFTT UP SFTFBSDI SFTPVSD FT UIBU BSF MJNJUFE XJUIJO UIF QSPWJODF EVF UP UIF IJHI DPTUT PG QIZTJDBM JOGSBTUSVDUVSF DBQJUBM FRVJQNFOU BOE TUBďOH ćJT JT CFJOH BDIJFWFE CZ FOTVSJOH UIBU BMM GBDJMJUJFT BSF VTFE PQUJNBMMZ IBWF EJWFSTJĕFE BDUJWJUZ UP LFFQ UIF SBUF PG VTF IJHI BOE FďDJFOU DPOTFRVFOUMZ JNQSPWJOH DPTU SFDPWFSZ BOE TVTUBJOBCMF PQFSB UJPOT #$13$ GBDJMJUJFT DPWFS UIF TQFDUSVN PG QSFDMJOJDBM SFTFBSDI DBQBCJMJUJFT BOE BSF QSPGFTTJPOBMMZ NBOBHFE CZ QFSTPOOFM XJUI FYQFSJFODF BOE USBDL SFDPSET JO QSFDMJOJDBM SFTFBSDI BOE CVTJ OFTT #$13$ JT SBQJEMZ HBUIFSJOH NPNFOUVN BT B 1SPWJODJBM BOE SFHJPOBM OFUXPSL PSHBOJ[BUJPO QSPWJEJOH DSJUJDBM TFSWJDFT UP UIF QSFDMJOJDBM SFTFBSDI DPNNVOJUZ BOE IBT SFDFJWFE TJHOJĕDBOU GVOEJOH GSPN UIF (PWFSONFOU PG $BOBEB BOE UIF 1SPWJODF PG #$ JODMVEJOH UIF 8FTUFSO &DPOPNJD %JWFSTJĕDBUJPO

t "DDFTT UP BO FYJTUJOH CPVUJRVF PG #$13$ DPSF TFSWJDFT t "DDFTT UP GBDJMJUJFT QFSTPOOFM TQFDJBMJ[FE FRVJQNFOU UIBU XPVME IFMQ EFGSBZ FYJTUJOH PQFSBUJPOBM DPTUT t "DDFTT UP BO FYJTUJOH GSPOU FOE PďDF PQFSBUJPO UP NBOBHF BOE USBDL QSFDMJOJDBM TFSWJDFT t "DDFTT UP B GPSVN GPS OFUXPSLJOH TQFDJBM FWFOUT USBJOJOH JOGPSNBUJPO TIBSJOH t 3FHJPOBM BCJMJUZ UP DPOEVDU TUVEJFT MPDBMMZ UIBU XPVME PUIFSXJTF CF PVUTPVSDFE JOBDDFTTJCMF Contact: %S 4BNVESB %JTTBOBZBLF .BOBHFS #VTJOFTT %FWFMPQNFOU Email: TEJTTBOBZBLF!CDQSD DB Tel: Photo: Compliments of MCW Consultants Ltd.

Corporate Profiles 2011.indd 12

2/15/11 7:31:16 PM

Supplied by

JPI<FE :FIGFI8K@FE

nnn%jpi\fe%Zfd

@ekif[lZ`e^ pfli e\n gXike\i `e X[mXeZ\[ i\j\XiZ_

@

n today’s research environment, shorter development cycles and intense competition are serious threats, and new drugs or medical devices often struggle to achieve their profit and volume objectives. Precise and comprehensive understanding of market opportunities, t herapeutic benef its, data capture technologies, regulatory controls, and site and patient recruitment are critical to overcoming these challenges.

A s a le ad i ng c l i n ic a l re s e a rc h organization specializing in the use of digital information systems for all aspects of global health sciences research, Syreon’s advanced computing technologies, specialized therapeutic and economic expertise and global reach combine to provide leading edge clinical and economic research programs ideally adapted to the fast pace of modern drug, diagnostics and device evaluation.

Syreon combines expertise in molecular medicine, biostatistics, clinical therapeutics, economics, health outcomes measurement, and economics to conduct national and international phase I to IV clinical studies. Our teams have extensive experience in all areas of clinical research, extending from developmental therapeutics to formal clinical trials and longitudinal disease-based registry studies in a broad range of therapeutic areas from infectious diseases to complex multisystem disorders.

J\im`Z\j Services encompass study development, project management, site recruitment and operation, data management, on-site monitoring, pharmacovigilance, medical writing, and statistical/ scientific analysis, health modeling and reporting. Advanced internet technologies provide immediate and continuous access for authorized research and clinical personnel for study communications or electronic data capture and reporting. Syreon studies are designed to be flexible and scalable and can incorporate from one to many hundreds of participating sites with continuous recording of multidimensional data in real time.

:c`eJki\Xd Working with an elite portfolio of global pharmaceutical partners Syreon developed ClinStream™, a proprietary electronic research system which links participants in the clinical research process in over 40 countries for the secure and seamless integration of genomic, laboratory, clinical, health and economic data.

>cfYXc i\XZ_

and China. These programs link Syreon, the study sponsor, and leading site investigators in a continuous process to guide the operation, analysis and publication of each study.

K_\iXg\lk`Z \og\ik`j\ Syreon studies span multiple therapeutic areas, and range from phase I new drug evaluation through longitudinal phase IV investigation of pharmacoeconomics and quality of life under conditions of normal clinical practice. Syreon has extensive expertise in each of these areas, from the design, analysis and statistical modeling of therapeutic information to the evaluation of health quality and economic outcome. Our clinical specialists have served as advisors to the biopharmaceutical industry and government in many aspects of clinical therapeutics and drug evaluation, and are involved in large international studies in this field.

Jpi\fe I\j\XiZ_ @ejk`klk\ JI@ In 2010 Syreon was pleased to announce the expansion of the Syreon Research Institute (SRI) as a desired provider for expert health economics research to the pharmaceutical and biotechnology sectors of Europe and North America. SRI represents an international team of highly focused professionals supported by powerful departments specializing in data management, statistical analysis and economic modeling to ensure that new products are optimally priced for rapid market uptake and are tightly aligned with patient and provider needs. Real-time monitoring of patient, provider, caregiver, community and institutional resource use is coupled with detailed cost vectors for each disease state to provide precise and dynamic estimation of direct and indirect costs of care, caregiver burden, and economic loss due to illness. Drawing together the unique perspectives of industry, government, and academia SRI is the ideal partner for helping your company move from product development to creating value, and realizing benefits in the shortest possible timeframe.

Syreon’s unique goal is to ensure excellence in the complex & rapidly changing world of healthcare, and our unprecedented repeat business rate is a ref lection of quality, reliability and commitment to our clients.

Contact: Michelle Dittrick Email: michelle.dittrick@syreon.com Tel: 604-676-5900

Syreon’s international investigator networks and multi-centre studies have enrolled from 30 to 30,000 subjects at more than 1000 sites spanning North America, South America, Western Europe, the Middle East, Eastern Europe, South Africa, Australia, Taiwan

Corporate Profiles 2011.indd 13

2/15/11 7:31:16 PM

KalGene specializes in converting promising oncology research into prescribable personalized medicine.

KalGene Pharmaceuticals Inc. (“Kalgene”) is a Canadian company focused on the development of oncology therapeutics and companion diagnostics. The company’s product pipeline is at various stages of research and development.

Its oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on breast, bladder, epithelial and thyroid cancers. KalGene is partnering with many of North America’s leading clinicianscientists and academic institutions to deliver personalized cancer diagnostics and drugs that maximize positive patient treatment outcomes.

www.kalgene.com

Corporate Profiles 2011.indd 14

2/15/11 7:31:27 PM

"EWBODJOH $BODFS $BSF 8JUI UIF PQFOJOH PG UIF $FOUSF GPS "EWBODFE %JBHOPTUJDT QBUJFOUT OPX IBWF JNNFEJBUF BDDFTT UP B 1&5 $5 TDBO UIF NPTU BEWBODFE NFEJDBM EJBHOPTUJD JNBHJOH UPPM BWBJMBCMF UPEBZ GPS UIF FBSMZ BOE BDDVSBUF EFUFDUJPO PG DBODFS 1BUJFOUT BSF TFFO XJUIJO B XFFL BU PVS QBUJFOU GPDVTFE TUBUF PG UIF BSU GBDJMJUZ HJWJOH UIFN WJUBM JOGPSNBUJPO UIFZ OFFE UP QMBO UIF CFTU USFBUNFOU

5

' o 8JMMJOHEPO (SFFO #VSOBCZ #$ 7 ( 1 NPB!QFU DU DB

:PV IBWF RVFTUJPOT 8F IBWF BOTXFST $BMM VT BU

XXX QFU DU DB

y

p

You have questions. We have answers.

Call us at 604 678 9274.

Corporate Profiles 2011.indd 15

2/17/11 1:59:07 PM

Core LifeSciences BC Members

U U

U U

U

U

U

Celator Pharmaceuticals Inc.

U

U

U

U

U U

U

U

U

U

U

iProgen

U

U

Kinexus Bioinformatics Corporation

U

U

MSI Methylation Sciences Inc.

U

Natural Pharma

U

U

U

U

U

U

U

U U

U

U

U

U

U

U

U U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U U

U

U

U

U

U U

U

U

U U

U

U U

U

U

U U

U

U

U

U U

U

U

U

U

U

U

U

U

Sirona Biochem

U

Tekmira Pharmaceuticals Corporation

U

U

U

U

U

Valocor Therapeutics, Inc.

U

U

U

U

U

U U

U

U

U

U

U

U

U

U

U U U

Xenon Pharmaceuticals Inc.

U

U

U

U

Zalicus Pharmaceuticals Ltd.

U

U

U

U

Zymeworks

U

U

U

U U

U

U

U

Neurological Diseases

U

U

U

Wex Pharmaceuticals Inc.

U

U

U

U

Vifor Pharma

U

U

U

U

OncoGenex Technologies Inc.

Welichem Biotech Inc.

Metabolic Diseases

U U

U

U

Sirius Genomics Inc.

U

U U

Neurodyn Inc.

SignalChem

U

U U

U

U

U

U

U

U

U

U

U

U

U

U

U U

U U

U

U

Qu Biologics Inc.

U

U

U

U

U U

U

Inimex Pharmaceuticals, Inc.

U

U

U

U

U

U

U

U

U U

I. G. MicroMed Environmental Inc.

QLT Inc.

U

U

U

iCo Therapeutics

U U

U

U

Globe Laboratories Inc.

Protox Therapeutics Inc.

U U

U

Farabloc Development Corp.

Ondine Biomedical Inc.

U U

U

U

GenomeDx Biosciences Inc.

Network Immunology Inc.

U

U

U

U U

U

U

Boreal Genomics

enGene Inc.

U

U

U

Cardiome Pharma Corp.

InďŹ&#x201A;ammatory Diseases

U

Infectious Diseases

U

Cardiovascular Diseases

U

U

Cancer

Aquinox Augurex Life Science Corp.

Autoimmune Diseases

U

Proteomics

U

U

Lab Reagents

U

U

Diseases High-Throughput Screening

U

U

Genomics

U

U

Gene Therapy

U

U

Drug Delivery

U

U

Bio-Processing

U

Angiotech Pharmaceuticals, Inc.

Tools

Vaccines

Amgen British Columbia Inc.

Therapeutics

U

Environmental

U

Diagnostics

U

Bioinformatics

U

Bio-Products

U

U

On Market

Phase 3 Clinical Studies

U

Allon Therapeutics Inc.

Pre-Clinical Studies

Alectos Therapeutics

Organizations

Drug Discovery

Phase 2 Clinical Studies

Fields of Study

Phase 1 Clinical Studies

Stage of Development

U

U

U U

U

U

U

U

U

U

U

U

U U U

U U

U

U

U U

U U

U U

U

U

U

U U

U

Please refer to www.lifesciencesbc.ca for further information on these companies.

Corporate Profiles 2011.indd 16

2/15/11 7:31:34 PM

Contract Research Organizations

Aurora Biomed Inc. BRI Biopharmaceutical Research Inc.

U

U

U

U

U

Strategic Consulting

Regulatory

U

U

U

U

U U

U

U

Enlighten Clinical Diagnostic Associates Inc.

U

U

U

U

U

GE Healthcare Bio-Sciences Inc. U

U U

U

Lifebank Corp.

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

PBR Laboratories

U U

Rondaxe

U

SBW Ltd

U

U

SignalChem

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U

U U

U

U

U

U

U

U

U

U U

Syreon Corporation

U U

U

U

U U

U

U

U

U

U U

PharmEng Technology

Wax-it Histology Services Inc.

U

U

I. G. MicroMed Environmental Inc.

PharmaNet

U

U U

Northern Lipids Inc.

UÊÊÊ U

CanReg Inc.

Healthmetrx (CEQAL)

Teaching and Training

Data Management and Statistics

U

Quality Assurance

Study Monitoring and Reporting

U

cGMP/GLP compliance

Phase IV Clinical Studies

U

Product Development

Phase III Clinical Studies

U

Contract Manufacturing

Phase II Clinical Studies

ASKA Research (a Division of Valerie Willetts & Associates)

General Services

Phase I Clinical Studies

Clinical Services

Toxicology

Pathology Services

Analytical Services

Bioanalytical Services

Organizations

Bioinformatics

Drug Discovery

Preclinical Services

U

U

U

U

U

U

U

U U

U

Please refer to www.lifesciencesbc.ca for further information on these companies.

LifeSciences British Columbia supports and represents the biopharmaceutical, medical

Growing Canada’s Bio-Economy

device, bioproducts & bioenergy, and greater life sciences community of British Columbia through leadership, advocacy and promotion of our world-class science and industry.

For more information, please visit www.lifesciencesbc.ca.

Corporate Profiles 2011.indd 17

2/15/11 7:31:38 PM

Medical Devices

U

Angiotech Pharmaceuticals, Inc. Arbutus Dental Centre

U

Biolux Research Ltd.

U

BioMers Products, LLC

U

U

U

Product Names – SimpliClear & ASTICS U

U

U

Developer U U U

U

U

U

U

U

U

(Regulatory Consultant) U

Evasc Medical Systems

U

U

U

U

Farabloc Development Corp.

U

Heart Force Medical

U U

U

U U

U

U

Neoteric Technology Limited

U

Neovasc Inc.

U U

U

U

Premier Diagnostic Health Services Inc

U

Progressive Health Innovations Inc. / AFX

U

U

U

(Transfusion) Blood management software

U

U

U

(Diabetes) U

LightIntegra

U

U

U

Photodisinfection

U

U

U

U

U

U

U

U

U Sports Med, Rehab, Athletic Training

Romich Medical Fund

U

U U

Women’s healthcare

Sorin Group

U

Starfish Medical

U

U

U

U

Cardiac

U

U

(Contract Manufacturing)

U

U

Ultrasonix U

U U

U

LifeScan Canada Ltd.

U

U

U

Kardium Inc.

U

U

U

Innovatek Medical Inc.

Urodynamix Technologies Ltd.

UÊ

U

Emergo Canada Consulting Inc.

Ondine Biomedical Inc.

U

Dental Service

Daan Diagnostics

LED Medical Diagnostics

OEM

Distributor

Other U

Manufacturer

Company Type

Device Design

Imaging

Testing Instruments

Medical Supplies

Dental Device

Organizations

Medical Equipment

Fields of Study

U

U

U U

U U

U

U

Please refer to www.lifesciencesbc.ca for further information on these companies.

Corporate Profiles 2011.indd 18

2/15/11 7:31:44 PM

Corporate Profiles 2011.indd 19

2/15/11 7:31:44 PM

Custom Crafted Intellectual Property Solutions

Science is in our DNA.

Patenting biotechnology advancements requires experience. And no one has more experience than Seed IP Law Group. With expertise in immunology, biochemistry and pharmacology, weâ&#x20AC;&#x2122;re a team of scientists who also understand the legal and business side of biotechnology.

A good idea is worth protecting, because history is written by people who patent.

206.622.4900

Corporate Profiles 2011.indd 20

www.SeedIP.com

701 Fifth Avenue, Seattle, WA 98104

2/15/11 7:31:46 PM